LIMERICK, Ireland, Dec. 9, 2021 /CNW/ - kneat.com, inc. (TSX:
KSI) ("Kneat or the Company") a leader in digitizing and
automating validation and quality processes, is
pleased to announce it has been ranked 3rd in the
prestigious 2021 Deloitte Ireland Technology Fast 50 list.
The Deloitte Technology Fast 50 Awards is one of Ireland's foremost technology award programs.
With Kneat's operational headquarters in Limerick, Ireland, the Company was included in the
ranking of the country's 50 fastest growing technology companies,
based on revenue growth over four years up until December
2020. Over this period, Kneat recorded growth of 1,661%,
whilst headcount increased 350%.
In addition to placing third overall, Kneat was also awarded
runner up for the Scale-Up Award, given to companies that have
demonstrated an impressive ability to scale up and expand
overseas.
"We are delighted with these awards and to be shortlisted with
so many other exceptional companies. We would like to thank
Deloitte, our customers, partners, shareholders, and our
outstanding high performing global teams", said Eddie Ryan, Chief Executive Officer of Kneat.
"It makes our team very proud that among our many clients we are
assisting seven of the world's top 10 pharmaceutical companies and
three of the world's leading COVID-19 vaccine manufacturers deliver
their medicines to the highest quality standards", continued
Ryan.
This award closes off a year which included several milestones
such as a public equity funding round of over $20 million CAD in April, the continued
acquisition and expansion of top biopharmaceutical clients,
record-setting revenue growth achievements and the Company's recent
uplisting to the Toronto Stock Exchange.
Read more about Kneat's achievements in 2021 here.
About Kneat
Kneat, a Canadian company with operational headquarters in
Limerick, Ireland, develops and
markets the next generation Kneat Gx software platform. Multiple
business work processes can be configured on the platform from
equipment to computer system validation, through to quality
document management.
Kneat's software allows users to author, review, approve,
execute testing online, manage any exceptions and post approve
final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex
Annex 11 compliant platform. Macro and micro report dashboards
enable powerful oversight into all systems, projects and processes
globally.
Customer case studies are reporting productivity improvements in
excess of 100% and a higher data integrity and compliance standard.
For more information visit www.kneat.com.
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein,
certain information presented constitutes "forward-looking
information" within the meaning of applicable Canadian securities
laws. Such forward-looking information includes, but is not limited
to, the relationship between Kneat and the customer, Kneat's
business development activities, the use and implementation
timelines of Kneat's software within the customer's validation
processes, the ability and intent of the customer to scale the use
of Kneat's software within the customer's organization and the
compliance of Kneat's platform under regulatory audit and
inspection. While such forward-looking statements are expressed by
Kneat, as stated in this release, in good faith and believed by
Kneat to have a reasonable basis, they are subject to important
risks and uncertainties. As a result of these risks and
uncertainties, the events predicted in these forward-looking
statements may differ materially from actual results or events.
These forward-looking statements are not guarantees of future
performance, given that they involve risks and uncertainties. The
forward-looking information in this press release does not include
a full assessment or reflection of the unprecedented impacts of the
COVID-19 pandemic occurring since the first quarter of 2020 and the
ongoing and developing resulting indirect global and regional
economic impacts. This has resulted in significant economic
uncertainty and even though the Company has to date experienced no
significant impact to its operations, any potential impact on our
future is difficult to understand or measure at this time.
Kneat does not undertake any obligation to release publicly
revisions to any forward-looking statement, except as may be
required under applicable securities laws. Investors should not
assume that any lack of update to a previously issued
forward-looking statement constitutes a reaffirmation of that
statement. Continued reliance on forward-looking statements is at
an investors' own risk.
SOURCE kneat.com, inc.